
Supplements and Featured Publications
- Year in Review: HER2+ Updates in Oncology
- Volume 1
- Issue 1
Dr. Ciombor on the FDA Approval of Trastuzumab Deruxtecan in HER2+ Metastatic Gastric Cancer
Kristen K. Ciombor, MD, MSCI, discusses the FDA approval of fam-trastuzumab deruxtecan-nxki in HER2-positive metastatic gastric cancer.
Kristen K. Ciombor, MD, MSCI, assistant professor of medicine, Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Vanderbilt-Ingram Cancer Center, discusses the FDA approval of fam-trastuzumab deruxtecan-nxki (Enhertu) in HER2-positive metastatic gastric cancer.
On January 15, 2021, the
Trastuzumab deruxtecan is a welcome addition to the gastric/GEJ cancer armamentarium, says Ciombor. However, as some patients will lose HER2 expression, routine biopsies are needed to determine whether the patient expresses the HER2 target and is still eligible to receive trastuzumab deruxtecan, Ciombor concludes.
Articles in this issue
about 4 years ago
Dr. Toppmeyer on Sequencing Therapy in HER2+ Breast Cancerabout 4 years ago
Dr. Krop Discusses Progress Made in Metastatic HER2+ Breast Cancerabout 5 years ago
Fleshing Out HER2-Directed Therapies in GI Malignancies


































